ORCID Profile
0000-0002-2060-5934
Current Organisation
Prefeitura Municipal de Belo Horizonte
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: FapUNIFESP (SciELO)
Date: 2019
DOI: 10.1590/0102-311X00115518
Abstract: Abstract: We evaluated adherence to highly active antiretroviral therapy (HAART) and its associated factors according to the type of regimen in patients initiating treatment in Belo Horizonte, Minas Gerais State, Brazil. We measured adherence using the eight items Morisky Therapeutic Adhesion Scale (MMAS-8) and compared the use of “backbone” tenofovir/lamivudine plus efavirenz one tablet once-daily (STR) or dolutegravir in multi-tablet once-daily (MTR-DTG), or other multi-tablet regimens (MTR-other). We conducted a multivariate logistic regression analysis to address factors associated with adherence. A total of 393 patients were included, 254 used STR, 106 MTR-DTG, and 33 MTR-other. The overall adhesion rate was 44.8% (95%CI: 39.4 50.1), 50% for MTR-DTG, 43.3% for STR and 39.4% for MTR-other. Multivariate analysis showed a higher chance of adherence among patients using MTR-DTG, those who received and understood counseling about their treatment and with a higher quality of life. Prior use of illicit drugs in the lifetime was associated with poorer adherence. Overall adherence was low, highlighting the need for strategies focusing on counseling about medicines and substance use. Pill burden was not an issue for patients using MTR-DTG once-daily, who achieved better results.
Publisher: Informa UK Limited
Date: 08-03-2020
Publisher: Research, Society and Development
Date: 18-05-2022
Abstract: Objetivos: Avaliar a eficácia da terapia dupla em in íduos submetidos à troca, mantendo carga viral 50 cópias/ml e em casos de troca por insuficiência renal, se houve alteração no clearance de cretinina, creatinina sérica e fósforo sérico. Metodologia: Coorte retrospectiva de in íduos 18 anois, que mudaram para terapia dupla, acompanhados por até 116 semanas e os resultados foram avaliados em 48 e/ou até 96 semanas após a troca. Os dados foram coletados no período de julho de 2020 a junho de 2021, por meio de pronbtuários e consulta so Sistema de Controle de Exames Laboratoriais (SISCEL) e ao Sistema de Controle Logístico de Medicamentos (SICLOM). As análises foram realizadas utilizando o software SPSS. Resultados: A maioria dos in íduos era do sexo masculino (65,5%), a média de idade na troca foi de 54,4 anos. O esquema de terapia dupla mais utilizado foi a associação DTG + 3TC (73,6%). O principal motivo de troca foi função renal prejudicada (40%), o medicamento mais descontinuado foi o TDF (55,79%). A maioria dos in íduos manteve a supressão viral por até 48 semanas após a troca (n=84, 96,8%). Dois in íduos (2,3%) não atingiram supressão viral neste período, com valores de 51 e 55 cópias/ml de vírus. Não houve alteração significativa na TFG comparando os níveis basais com 48 semanas após a troca. Quanto ao fósforo, comparando o valor basal, com o valor medido 48-96 semans após a troca houve discreto aumento, com significância estatística (2,70 ± 0,76 mg/dl vs. 3,14 ± 0,47 p = 0,026). Conclusão: A maioria dos in íduos manteve a supressão viral em até 48 e/ou até 96 semanas, demonstrando efetividade da terapia dupla. Entre os que trocaram por insuficiência renal, não houve melhora da taxa de filtração glomerular em 48 semans, mas observou-se aumento da excreção de fósforo, o que requer mais estudos, com amostra maior e seguimento mais longo.
Publisher: Springer Science and Business Media LLC
Date: 16-07-2022
DOI: 10.1007/S10461-022-03737-Y
Abstract: We examined trends in the prevalence of post-exposure prophylaxis following sexual exposure (PEPSE) per million population (2011-2019) and the proportion of repeated PEPSE within 365 days of the first PEPSE dispensing (2011-2018) in Brazil. We also compared the prevalence of repeated PEPSE according to patient and health services characteristics in 2018. The prevalence of PEPSE increased 55.5% from 2011 to 2019. Repeated PEPSE increased 11.8%, reaching 8.4% among people with their first dispensing in 2018. The prevalence of repeated PEPSE was higher in cis men or trans women (versus cisgender women) homosexuals (versus heterosexuals) and people aged 25-29 years (versus other age groups). We also observed greater prevalence of repeated PEPSE in HIV services in populous cities or services with elevated caseloads. Our findings highlight the need for strategies to reduce repeated PEPSE and promote other HIV-prevention technologies, particularly among young adults, cisgender men, transgender women, and homosexuals.
No related grants have been discovered for simone furtado dos santos.